Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide

被引：154
|
作者：
Enting, RH
Demopoulos, A
DeAngelis, LM
Abrey, LE
机构：
[1] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[2] Univ Groningen Hosp, Dept Neurol, Groningen, Netherlands
来源：
NEUROLOGY | 2004年 / 63卷 / 05期
关键词：
D O I：
10.1212/01.WNL.0000137050.43114.42
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.
引用
收藏
页码：901 / 903
页数：3
相关论文
共 50 条
  • [21] HIGH-DOSE METHOTREXATE, RITUXIMAB, AND TEMOZOLOMIDE (M/R/T) FOR PATIENTS WITH PRIMARY CNS LYMPHOMA (PCNSL)
    Gerstner, Elizabeth
    Hochberg, Fred
    Plotkin, Scott
    Eichler, April
    Batchelor, Tracy
    NEURO-ONCOLOGY, 2009, 11 (05) : 627 - 627
  • [22] Therapy of primary CNS lymphoma
    Pels, H
    Glasmacher, A
    Schmidt-Wolf, IGH
    Schlegel, U
    AKTUELLE NEUROLOGIE, 2001, 28 (04) : 189 - 194
  • [23] Primary temozolomide chemotherapy in elderly patients with primary CNS lymphoma (PCNSL)
    Herrlinger, U
    Uhl, M
    Weller, M
    ANNALS OF ONCOLOGY, 2005, 16 : 167 - 167
  • [24] Primary temozolomide chemotherapy in elderly patients with primary CNS lymphoma (PCNSL)
    Herrlinger, U
    Uhl, M
    Weller, M
    NEURO-ONCOLOGY, 2005, 7 (03) : 314 - 315
  • [25] Methotrexate, rituximab, anti temozolomide in CNS lymphoma: The Mayo Clinic experience.
    Gupta, Vinay
    Wolf, Robert C.
    Johnston, Patrick B.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] RITUXIMAB MONOTHERAPY FOR PATIENTS WITH RECURRENT PRIMARY CNS LYMPHOMA
    Batchelor, T. T.
    Grossman, S. A.
    Mikkelsen, T.
    Ye, X.
    Desideri, S.
    Lesser, G. J.
    NEUROLOGY, 2011, 76 (10) : 929 - 930
  • [27] PCV salvage chemotherapy for recurrent primary CNS lymphoma
    Herrlinger, U
    Brugger, W
    Bamberg, M
    Küker, W
    Dichgans, J
    Weller, M
    NEUROLOGY, 2000, 54 (08) : 1707 - 1708
  • [28] TREATMENT FOR PRIMARY CNS LYMPHOMA WITH HIGH-DOSE MTX AND SALVAGE THERAPY WITH ESHAP
    Kanno, Hiroshi
    Hayashi, Akimune
    Sato, Hidemitsu
    Tateishi, Kensuke
    Kawahara, Nobutaka
    NEURO-ONCOLOGY, 2009, 11 (06) : 970 - 970
  • [29] Successful use of intraventricular and intravenous rituximab therapy for refractory primary CNS lymphoma in a child
    Akyuz, Canan
    Aydin, G. Burca
    Cila, Aysenur
    Akalan, Nejat
    Soylemezoglu, Figen
    Cengiz, Mustafa
    Yazici, Nalan
    Buyukpamukcu, Munevver
    LEUKEMIA & LYMPHOMA, 2007, 48 (06) : 1253 - 1255
  • [30] Salvage therapy for primary central nervous system lymphoma with 90Y-Ibritumomab and Temozolomide
    Pitini, V
    Arrigo, C.
    Naro, C.
    Baldari, S.
    Altavilla, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 189 - 189
12345